Literature DB >> 26527788

Randomized Comparison of Surveillance Intervals in Familial Colorectal Cancer.

Simone D Hennink1, Andrea E van der Meulen-de Jong1, Ron Wolterbeek1, A Stijn L P Crobach1, Marco C J M Becx1, Wiet F S J Crobach1, Michiel van Haastert1, W Rogier Ten Hove1, Jan H Kleibeuker1, Maarten A C Meijssen1, Fokko M Nagengast1, Marno C M Rijk1, Jan M J I Salemans1, Arnold Stronkhorst1, Hans A R E Tuynman1, Juda Vecht1, Marie-Louise Verhulst1, Wouter H de Vos Tot Nederveen Cappel1, Herman Walinga1, Olaf K Weinhardt1, Dik Westerveld1, Anne M C Witte1, Hugo J Wolters1, Annemieke Cats1, Roeland A Veenendaal1, Hans Morreau1, Hans F A Vasen2.   

Abstract

PURPOSE: Colonoscopic surveillance is recommended for individuals with familial colorectal cancer (CRC). However, the appropriate screening interval has not yet been determined. The aim of this randomized trial was to compare a 3-year with a 6-year screening interval. PATIENTS AND METHODS: Individuals between ages 45 and 65 years with one first-degree relative with CRC age < 50 years or two first-degree relatives with CRC were selected. Patients with zero to two adenomas at baseline were randomly assigned to one of two groups: group A (colonoscopy at 6 years) or group B (colonoscopy at 3 and 6 years). The primary outcome measure was advanced adenomatous polyps (AAPs). Risk factors studied included sex, age, type of family history, and baseline endoscopic findings.
RESULTS: A total of 528 patients were randomly assigned (group A, n = 262; group B, n = 266). Intention-to-treat analysis showed no significant difference in the proportion of patients with AAPs at the first follow-up examination at 6 years in group A (6.9%) versus 3 years in group B (3.5%). Also, the proportion of patients with AAPs at the final follow-up examination at 6 years in group A (6.9%) versus 6 years in group B (3.4%) was not significantly different. Only AAPs at baseline was a significant predictor for the presence of AAPs at first follow-up. After correction for the difference in AAPs at baseline, differences between the groups in the rate of AAPs at first follow-up and at the final examination were statistically significant.
CONCLUSION: In view of the relatively low rate of AAPs at 6 years and the absence of CRC in group A, we consider a 6-year surveillance interval appropriate. A surveillance interval of 3 years might be considered in patients with AAPs and patients with ≥ three adenomas.
© 2015 by American Society of Clinical Oncology.

Entities:  

Mesh:

Year:  2015        PMID: 26527788     DOI: 10.1200/JCO.2015.62.2035

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  10 in total

1.  Screening colonoscopy intervals in familial colorectal cancer.

Authors:  Matthew F Kalady
Journal:  Transl Gastroenterol Hepatol       Date:  2016-03-16

2.  Colorectal Cancer Screening in the Non-Syndromic Familial Risk Population: Is It Time to Revise the Clinical Guidelines?

Authors:  Enrique Quintero; Antonio Z Gimeno-García
Journal:  Am J Gastroenterol       Date:  2017-10-31       Impact factor: 10.864

3.  CT Colonographic Screening of Patients With a Family History of Colorectal Cancer: Comparison With Adults at Average Risk and Implications for Guidelines.

Authors:  Perry J Pickhardt; Ifeanyi Mbah; B Dustin Pooler; Oliver T Chen; J Louis Hinshaw; Jennifer M Weiss; David H Kim
Journal:  AJR Am J Roentgenol       Date:  2017-01-26       Impact factor: 3.959

4.  Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG).

Authors:  Kevin J Monahan; Nicola Bradshaw; Sunil Dolwani; Bianca Desouza; Malcolm G Dunlop; James E East; Mohammad Ilyas; Asha Kaur; Fiona Lalloo; Andrew Latchford; Matthew D Rutter; Ian Tomlinson; Huw J W Thomas; James Hill
Journal:  Gut       Date:  2019-11-28       Impact factor: 23.059

5.  Evidence for genetic association between chromosome 1q loci and predisposition to colorectal neoplasia.

Authors:  Stephanie A Schubert; Dina Ruano; Fadwa A Elsayed; Arnoud Boot; Stijn Crobach; Arantza Farina Sarasqueta; Bruce Wolffenbuttel; Melanie M van der Klauw; Jan Oosting; Carli M Tops; Ronald van Eijk; Hans Fa Vasen; Rolf Ham Vossen; Maartje Nielsen; Sergi Castellví-Bel; Clara Ruiz-Ponte; Ian Tomlinson; Malcolm G Dunlop; Pavel Vodicka; Juul T Wijnen; Frederik J Hes; Hans Morreau; Noel Fcc de Miranda; Rolf H Sijmons; Tom van Wezel
Journal:  Br J Cancer       Date:  2017-07-25       Impact factor: 7.640

6.  Improvement Effect of Bifidobacterium animalis subsp. lactis MH-02 in Patients Receiving Resection of Colorectal Polyps: A Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Hui Liu; Kaige Zhang; Peng Liu; Xuan Xu; Yuyang Zhou; Lihong Gan; Ling Yao; Bin Li; Tingtao Chen; Nian Fang
Journal:  Front Immunol       Date:  2022-06-27       Impact factor: 8.786

7.  Hereditary cancer registries improve the care of patients with a genetic predisposition to cancer: contributions from the Dutch Lynch syndrome registry.

Authors:  Hans F A Vasen; Mary E Velthuizen; Jan H Kleibeuker; Fred H Menko; Fokke M Nagengast; Annemieke Cats; Andrea E van der Meulen-de Jong; Martijn H Breuning; Anne J Roukema; Inge van Leeuwen-Cornelisse; Wouter H de Vos Tot Nederveen Cappel; Juul T Wijnen
Journal:  Fam Cancer       Date:  2016-07       Impact factor: 2.375

8.  Identification of familial colorectal cancer and hereditary colorectal cancer syndromes through the Dutch population-screening program: results ofa pilot study.

Authors:  Sanne J H van Erp; Laura W Leicher; Simone D Hennink; Zeinab Ghorbanoghli; Simone A C Breg; Hans Morreau; Maartje Nielsen; James C H Hardwick; Jan A Roukema; Alexandra M J Langers; Wouter H de Vos Tot Nederveen Cappel; Hans F A Vasen
Journal:  Scand J Gastroenterol       Date:  2016-06-16       Impact factor: 2.423

9.  Lack of association between screening interval and cancer stage in Lynch syndrome may be accounted for by over-diagnosis; a prospective Lynch syndrome database report.

Authors:  Toni T Seppälä; Aysel Ahadova; Mev Dominguez-Valentin; Finlay Macrae; D Gareth Evans; Christina Therkildsen; Julian Sampson; Rodney Scott; John Burn; Gabriela Möslein; Inge Bernstein; Elke Holinski-Feder; Kirsi Pylvänäinen; Laura Renkonen-Sinisalo; Anna Lepistö; Charlotte Kvist Lautrup; Annika Lindblom; John-Paul Plazzer; Ingrid Winship; Douglas Tjandra; Lior H Katz; Stefan Aretz; Robert Hüneburg; Stefanie Holzapfel; Karl Heinimann; Adriana Della Valle; Florencia Neffa; Nathan Gluck; Wouter H de Vos Tot Nederveen Cappel; Hans Vasen; Monika Morak; Verena Steinke-Lange; Christoph Engel; Nils Rahner; Wolff Schmiegel; Deepak Vangala; Huw Thomas; Kate Green; Fiona Lalloo; Emma J Crosbie; James Hill; Gabriel Capella; Marta Pineda; Matilde Navarro; Ignacio Blanco; Sanne Ten Broeke; Maartje Nielsen; Ken Ljungmann; Sigve Nakken; Noralane Lindor; Ian Frayling; Eivind Hovig; Lone Sunde; Matthias Kloor; Jukka-Pekka Mecklin; Mette Kalager; Pål Møller
Journal:  Hered Cancer Clin Pract       Date:  2019-02-28       Impact factor: 2.857

10.  Elevated serum triglyceride predicts recurrence of colorectal polyps in patients with advanced adenomas.

Authors:  Boying Liu; Pingwu Wen; Xiaodong Gu; Ruiqiang Weng; Sudong Liu
Journal:  Lipids Health Dis       Date:  2020-09-23       Impact factor: 3.876

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.